LOGIN  |  REGISTER
C4 Therapeutics

Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023

September 20, 2023 | Last Trade: US$1.44 0.00 0.00

MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul Lévesque, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Fitzgerald Global Healthcare Conference 2023 being held September 26-28 in New York City.

Presentation Details
  
Date:Wednesday, September 27, 2023
Time:8:00 - 8:30 AM EDT in Track 2
Location:Intercontinental Barclay New York Hotel

Mr. Lévesque and Mr. Philippe Dubuc, Senior Vice President and Chief Financial Officer, will also be available for 1x1 investor meetings.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and Twitter.

Contacts:

Investor Inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
438-315-6608

Astria Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page